TABLE 2

Protection obtained by immunization with dimeric OspC at clinically relevant dosages

GroupNo. of cultures positive/total no.No. of mice positive/total no.% mice protected
SkinEarJointBladderHeartAll sites
Alum only6/66/66/66/66/630/306/60
0.1 μg D-OspCB31 + alum1/61/60/61/61/64/301/683
1.0 μg D-OspCB31 + alum0/60/60/60/60/60/300/6100
10 μg D-OspCB31 + alum1/60/61/61/61/64/301/683
0.1 μg M-OspCB31 + alum3/33/33/33/33/315/153/30
1.0 μg M-OspCB31 + alum3/33/33/33/33/315/153/30
10 μg M-OspCB31 + alum2/32/32/32/32/310/152/333
100 μg M-OspCB31 + alum4/64/64/64/64/620/304/633